Vericiguat as a Novel Ferroptosis Inhibitor Alleviates Doxorubicin‐Induced Cardiotoxicity
These findings indicate that vericiguat protects against doxorubicin-induced myocardial ferroptosis, positioning it as a promising therapeutic candidate for DIC and a novel ferroptosis inhibitor.
Authors
- Y. J. Wang
- Haiqiong Liu
- Y. Zhang
- Zhiyin Zhang (ORCID: https://orcid.org/0000-0003-2335-228X)
- C X Liu
- Tao Luo (ORCID: https://orcid.org/0000-0002-3415-3676)
- Huan Han (ORCID: https://orcid.org/0000-0003-0537-3191)
- Jiahao Wen (ORCID: https://orcid.org/0000-0002-7175-653X)
- Shuwen Huang
- Ziwei Zhang
- Wen Ou
- Xianbao Wang
- Wenjun Luo
Institutions
- Zunyi Medical University (CN)
- University of California, Irvine (US)
- Fuwai Yunnan Cardiovascular Hospital (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- Guangzhou Development Zone Hospital (CN)
- Zhujiang Hospital (CN)
- Guangdong Provincial Center for Disease Control and Prevention (CN)
- Guangdong Provincial People's Hospital (CN)
- 421 Hospital of PLA (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Basic & Clinical Pharmacology & Toxicology
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1111/bcpt.70219
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00